The Filing Desk

Elanco vs Perrigo

Elanco ELAN · Perrigo PRGO · Pharmaceuticals

Elanco reported revenue of $4.7 billion in fiscal 2025, about the same as Perrigo's $4.3 billion in fiscal 2025. Elanco's revenue grew 6.2% in its latest year, and Perrigo's fell 2.8%. Free cash flow was $284 million at Elanco and $145 million at Perrigo.

Side by side

ElancoPerrigo
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$4.7B$4.3B
Revenue growth6.2%−2.8%
Revenue growth a year, last 5 years7.6%0.8%
Gross margin55.0%35.1%
Operating margin—−26.4%
Net margin−4.9%−33.5%
Free cash flow$284M$145M
Free cash flow margin6.0%3.4%
Return on capital−0.1%−13.2%
Net debt to EBITDA5.2x—
Dividends and buybacks$0M$159M
Change in diluted share count−0.2%0.8%
Last close$22.96$15.82
P/E at the last close——
Insider trades, last 12 monthsbought $2.6 million, sold $100,050bought $106,350, sold $0
Piotroski F-score6 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ElancoPerrigo
Operating margin
Percent of revenue
ElancoPerrigo
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ElancoPerrigo

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Elanco and Perrigo pages.